Document is current
Any future updates will be listed below
-
Authors
Lindskrog, Sia Viborg http://orcid.org/0000-0001-5280-7306
Prip, Frederik
Lamy, Philippe http://orcid.org/0000-0003-1347-7724
Taber, Ann http://orcid.org/0000-0002-0516-9564
Groeneveld, Clarice S. http://orcid.org/0000-0001-5222-2586
Birkenkamp-Demtröder, Karin http://orcid.org/0000-0001-8057-6277
Jensen, Jørgen Bjerggaard
Strandgaard, Trine
Nordentoft, Iver http://orcid.org/0000-0003-4856-4086
Christensen, Emil http://orcid.org/0000-0001-7201-3933
Sokac, Mateo
Birkbak, Nicolai J. http://orcid.org/0000-0003-1613-9587
Maretty, Lasse
Hermann, Gregers G.
Petersen, Astrid C.
Weyerer, Veronika
Grimm, Marc-Oliver
Horstmann, Marcus
Sjödahl, Gottfrid http://orcid.org/0000-0002-7869-0473
Höglund, Mattias
Steiniche, Torben
Mogensen, Karin
de Reyniès, Aurélien
Nawroth, Roman
Jordan, Brian
Lin, Xiaoqi
Dragicevic, Dejan
Ward, Douglas G.
Goel, Anshita
Hurst, Carolyn D.
Raman, Jay D.
Warrick, Joshua I. http://orcid.org/0000-0001-6149-1331
Segersten, Ulrika
Sikic, Danijel
van Kessel, Kim E. M.
Maurer, Tobias
Meeks, Joshua J.
DeGraff, David J.
Bryan, Richard T.
Knowles, Margaret A.
Simic, Tatjana
Hartmann, Arndt
Zwarthoff, Ellen C.
Malmström, Per-Uno
Malats, Núria http://orcid.org/0000-0003-2538-3784
Real, Francisco X. http://orcid.org/0000-0001-9501-498X
Dyrskjøt, Lars http://orcid.org/0000-0001-7061-9851
-
Funding
Funding for this research was provided by:
L.D. is supported by the following funding sources: Aarhus University, The Danish Cancer Biobank, The Danish Cancer Society.
- License Information
-
More Information
Article History
Received: 11 June 2020
Accepted: 9 March 2021
First Online: 16 April 2021
Competing interests
: L.D. has sponsored research agreements with C2i-genomics, Natera, AstraZeneca and Ferring, and has an advisory/consulting role at Ferring. J.B.J. has sponsored research agreements with Medac, Photocure ASA, Cephaid, Nucleix, Astellas and Ferring, and has an advisory board role at Olympus Europe, Cephaid and Ferring. J.D.R. is involved in a sponsored scientific study or trial with Pacific Edge Biotechnologies, MDxHealth and Urogen Pharma, is a consultant for Urogen Pharma, and has an investment interest in American Kidney Stone Management. J.J.M. is a consultant for Ferring, AstraZeneca, Janssen and participated in advisory boards for Foundation Medicine and Nucleix. R.T.B. has contributed to advisory boards for Olympus Medical Systems & Janssen, and undertakes research funded by UroGen Pharma and QED Therapeutics. The following authors declare no competing interests: S.V.L., F.P., P.L., A.T., C.S.G., K.B.D., T.S., I.N., E.C., M.S., N.J.B., L.M., G.G.H., A.C.P., V.W., M.O.G., M.H., G.S., M.H., T.S., K.M., A.R., R.M., B.J., X.L., D.D., D.G.W., A.G., C.D.H., J.I.W., U.S., D.S., K.E.M.K., T.M., D.J.D., M.A.K., T.S., A.H., E.C.Z., P.U.M., N.M., and F.X.R.
